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Abstract
Aims/hypothesis Variations in FTO are the strongest common
genetic determinants of adiposity, and may partly act by
influencing dopaminergic signalling in the brain leading to al-
tered reward processing that promotes increased food intake.
Therefore, we investigated the impact of such an interaction on
body composition, and peripheral and brain insulin sensitivity.
Methods Participants from the Tübingen Family study
(n=2245) and the Malmö Diet and Cancer study (n=2921)
were genotyped for FTO SNP rs8050136 and ANKK1 SNP
rs1800497. Insulin sensitivity in the caudate nucleus, an
important reward area in the brain, was assessed by fMRI in
45 participants combined with intranasal insulin administration.
Results We found evidence of an interaction between
variations in FTO and an ANKK1 polymorphism that
associates with dopamine (D2) receptor density. In cases of
reduced D2 receptor availability, as indicated by the ANKK1
polymorphism, FTO variation was associated with increased
body fat and waist circumference and reduced peripheral
insulin sensitivity. Similarly, altered central insulin sensitivity
was observed in the caudate nucleus in individuals with the
FTO obesity-risk allele and diminished D2 receptors.
Conclusions/interpretation The effects of variations in FTO
are dependent on dopamine D2 receptor density (determined
by the ANKK1 polymorphism). Carriers of both risk alleles
might, therefore, be at increased risk of obesity and diabetes.
Keywords ANKK1 . Body fat . Dopamine . FTO . Insulin
sensitivity . TaqIA
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Introduction
The prevalence of obesity and diabetes is increasing
dramatically worldwide. In addition to behavioural factors,
such as changes in eating habits and lack of physical activity,
hereditary factors strongly determine body weight [1].
Variations in the fat mass and obesity-associated gene (FTO)
are currently the strongest known genetic factors that
predispose humans to non-monogenic obesity [2–4].
Carriers of the risk allele are more liable to have a higher
BMI due to increased energy intake [5, 6] and decreased
satiety [7]. Underlying mechanisms may include altered
postprandial responses in reward- and appetite-regulating
brain areas [8, 9], and impaired postprandial suppression
of the hunger hormone ghrelin [9]. In addition, FTO
polymorphisms are a common genetic determinant for type
2 diabetes, particularly via their effects on adiposity [2, 10].
Interestingly, recent data indicate that FTO variations
determine mitochondrial activity via a network that involves
expressional changes in IRX3 and IRX5 [11, 12]. In addition
to associations with adipocyte function [12], FTO
polymorphisms influence the expression of IRX3 in the human
brain [11]. FTO variations have also been shown to coincide
with altered regulation of a molecular network including
RPGRIP1L in neuronal cells that ultimately leads to altered
cellular function and potentially promotes adiposity [13].
Recent work in rodent models suggests that variations in
Fto may be linked to increased food intake and obesity
through an influence on dopamine signalling [14].
Dopamine neurons express Fto. Conditional loss of Fto in
dopamine neurons specifically impairs dopamine receptor
type 2/3 (D2/D3)-mediated neuronal act ivat ion.
Accordingly, Fto-deficient mice show altered D2/D3
receptor-dependent regulation of locomotor activity and
reward sensitivity. These findings also highlight the
possibility that Fto influences food intake by altering D2
receptor-dependent feeding behaviour.
In terms of metabolism, dopamine signalling is crucial for
the regulation of whole-body insulin sensitivity [15]. Deep
brain stimulation of dopaminergic areas in the brain modulates
glucose metabolism and body weight in rodents [16, 17].
Accordingly, the dopamine receptor agonist bromocriptine
improves insulin sensitivity and induces weight loss in
humans [18], and is therefore approved for the treatment of
type 2 diabetes in some countries [18]. On a cellular level,
there is clear evidence for an interaction between insulin and
dopamine signalling [19–21] in the regulation of reward and
food intake [22, 23].
Therefore, one possible hypothesis is that variations in
FTO affect dopaminergic regulation of insulin sensitivity,
thereby influencing body weight. Indeed, the FTO risk allele
is linked to central insulin resistance [24]. Furthermore, there
is evidence that central insulin regulates peripheral insulin
sensitivity [25–29]. However, the well-known associations
of FTO variants with whole-body insulin sensitivity [30–32]
and diabetes risk [2, 10] are mainly driven by associations
with BMI [2, 10, 31].
Alterations in dopamine signalling via D2 receptors are
linked to common genetic variations. The TaqIA restriction
fragment length polymorphism (rs1800497) is located in the
ankyrin repeat and protein kinase domain-containing protein
(ANKK1) gene approximately 9 kb downstream of the D2
receptor gene [33]. In candidate gene studies, carriers of the
risk allele (T allele) show diminished D2 receptor density
[34, 35], reduced D2 receptor binding potential [36] and an
increased risk of substance abuse [37]. With regard to food
intake, carriers of the ANKK1 risk allele have reduced
responses to palatable and energy-dense food in brain regions
involved in reward processing [38]. While the polymorphism
is not a major determinant of body weight per se [39], carriers
of the risk allele have difficulty losing or maintaining body
weight [39, 40]. Specifically, an attenuated response to food in
the striatum of risk-allele carriers was a predictor of further
weight gain [41]. A recent study in humans identified an
interaction between FTO and ANNK1 polymorphisms that
determines midbrain activity during reward learning [42].
Since there is evidence that both FTO and ANKK1 confer
risk for obesity by their influence on D2 receptors, we
investigated whether common variations in these two genes
interact to increase the risk for high body weight,
unfavourable body fat distribution, altered glucose
metabolism and decreased insulin sensitivity of the whole
body, as well as of the brain, specifically the striatum
(including the putamen, pallidum and caudate nucleus).
Such an interaction would be relevant given that
approximately 30% of all populations carry at least one risk
allele of both variants (mean minor allele frequency of FTO
and ANKK1 in various populations is approximately 33%
according to 1000 genomes data [www.1000genomes.org;
accessed 20 May 2015]). Moreover, the presence of an
interaction would highlight the importance of the role of
FTO in dopamine signalling in humans.
Methods
Participants of the Tübingen Family cohort The Tübingen
Family (TUEF) study is an ongoing project that includes
Europid volunteers from southern Germany who have an
elevated risk of type 2 diabetes but do not have manifest
diabetes [28]. Subjects are recruited by personal contact as
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well as via local advertisements, for example in newspapers.
All participants are metabolically characterised by a 75 g
OGTT (see details below). Less than 5% of the cohort are
related. Exclusion criteria include major medical and
psychiatric diseases, as well as treatment with medication for
weight loss or blood glucose control. Informed written
consent is obtained from all participants, and the local ethics
committee have approved the protocol.
We included 2245 TUEF study participants with a BMI
<40 kg/m2 in the current analyses. Based on ADA criteria
for glucose tolerance, 1588 had normal glucose tolerance,
224 had impaired fasting glucose, 189 had impaired glucose
tolerance, 124 displayed both impaired fasting glucose and
impaired glucose tolerance, and 120 had type 2 diabetes.
The clinical characteristics of the TUEF study population are
presented in Table 1. For all participants, total body fat and
lean body mass were measured by bioelectrical impedance
(BIA-101; RJL Systems, Detroit, MI, USA).
Participants of the MDC CA reinvestigation cohort The
Malmö Diet and Cancer (MDC) study is a population-based
cohort collected in Malmö, southern Sweden. Between 1991
and 1996, 30,000 individuals born between 1923 and 1950
were recruited to the study, from which, 6103 non-related
individuals were randomly selected to take part in the MDC
CA (cardiovascular arm) study. All selected individuals who
were alive and had not emigrated from Sweden (n=4924)
were invited to a re-examination starting in 2007. Of these,
3734 accepted and underwent a standard 75 g OGTT. All
participants provided written informed consent, and the study
was approved by the Lund University ethics review
committee.
Genotyping For the TUEF cohort, DNA from whole blood
was isolated with a commercial DNA isolation kit
(NucleoSpin, Macherey – Nagel, Düren, Germany).
Genotyping for FTO SNP rs8050136 and ANKK1 SNP
rs1800497 was performed by mass spectrometry
(Sequenom, Hamburg, Germany). The genotypes validated
by bidirectional sequencing in 50 participants were 100%
identical. Minor allele frequencies were 43% for the FTO A
risk allele and 19% for the ANKK1 T risk allele. Both SNPs
were in Hardy–Weinberg equilibrium (HWE; FTO SNP
p=0.7, ANKK1 SNP p=0.2).
The MDC cohort was genotyped at the Broad genotyping
facility (Cambridge, MA, USA) using the Illumina
OmniExpressExome Beadchip v1.0 B array (Illumina, San
Diego, CA, USA). Genotypes were called using the Gencall
algorithm in Genomestudio (Illumina) with refinement of rare
variants with missing calls undertaken using zCall [43].
Standard quality control filters were applied. In brief, SNPs
were excluded if they were monomorphic, had a low call rate
(<99%) or deviated from HWE (p< 10−4). Samples were
excluded if they were duplicates, unexpected first/second
relatives, sex mismatched, heterozygosity outliers (>3 SD
from mean), ancestral outliers or had a low call rate (<95%).
No principal component adjustment was used since the
population was homogeneous and participants were recruited
at a single centre. Both SNPs were in HWE (FTO SNP p=0.6,
ANKK1 SNP p=0.8).
OGTTA 75 g OGTTwas performed as previously described
[44]. In the TUEF participants, glucose, insulin and C-peptide
were measured five times during the experiment (0, 30, 60, 90
and 120 min). For the MDC cohort, blood samples were
obtained at 0, 30 and 120 min.
Hyperinsulinaemic–euglycaemic clamp In a subgroup of
499 participants, insulin sensitivity was assessed using a
hyperinsulinaemic-euglycaemic glucose clamp as previously
described [44]. The clamp-derived insulin sensitivity index
was calculated by dividing the mean glucose infusion rate
during steady state by the plasma insulin concentrations
during this time [44].
Analytical procedures In the TUEF study, plasma glucose
was measured by the glucose-oxidase method (Yellow
Springs Instruments, Yellow Springs, OH, USA). Insulin
and C-peptide concentrations were measured using
commercial chemiluminescence assays for ADVIA Centaur
(Siemens Medical Solutions, Fernwald, Germany). In the
MDC study, plasma glucose was measured using a glucose
dehydrogenase method (Hemocue, Ängelholm, Sweden) and
serum insulin was measured using ELISA (Dako, Glostrup,
Denmark).
fMRI Forty-five healthy volunteers (19 women, 26 men;
mean age 26.4±3.4 years) underwent fMRI to assess regional
insulin action in the brain. They were retrospectively
Table 1 Clinical characteristics of the TUEF and MDC study
populations
TUEF cohort MDC cohort
Sex (female/male) 1416/829 1411/974
Age (years) 40.9 ± 13.9 72.4 ± 5.6
BMI (kg/m2) 27.7 ± 5.3 26.6 ± 4.1
Percentage body fat (%) 31± 11 25± 7 (subgroup
of n = 1279)
Waist circumference (cm) 92± 14 92± 12
Fasting glucose (mmol/l) 5.2 ± 0.7 5.9 ± 0.7
Glucose, 120 min OGTT (mmol/l) 6.6 ± 2.7 7.2 ± 2.8
HbA1c (%) 5.4 ± 0.5 –
HbA1c (mmol/mol) 35.5 ± 5.3 –
Data are presented as means ± SD
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genotyped for the two SNPs of interest. Eleven individuals
were homozygous for both non-risk major alleles (FTO
rs8050136 and ANKK1 rs1800497), 20 were homozygous
major allele carriers of the ANKK1 SNP and homozygous
minor allele carriers of the FTO SNP, five were homozygous
minor allele carriers of the ANKK1 SNP and homozygous for
the FTO SNP major allele, and nine were homozygous for the
minor alleles of both polymorphisms.
Experiments were conducted after an overnight fast of at
least 10 h and commenced at 07:00 hours with a ‘resting state’
fMRI measurement under basal conditions. Following the
basal measurement, 160 U of human insulin was administered
via intranasal spray as previously described [28, 45]. After
30 min, a second ‘resting state’ fMRI measurement was
performed.
fMRI data acquisitionWhole-brain fMRI data was obtained
with a 3.0 T scanner (Siemens Tim Trio, Erlangen, Germany).
Functional data were collected by echo-planar imaging
sequence: repetition time 2 s, echo time 30 ms, field of view
210 mm2, matrix 64 × 64, flip angle 90°, voxel size
3.3×3.3×3.6 mm3, slice thickness 3.6 mm, 1 mm gap and
the images were acquired in ascending order. Each brain
volume comprised 26 axial slices and each functional run
contained 176 image volumes, resulting in a total scan time
of 6.04 min. In addition, high-resolution T1 weighted
anatomical images (MPRage: 192 slices, matrix: 256×224,
1×1×1 mm3) of the brain were obtained.
Fractional amplitude of low-frequency fluctuation
Low-frequency (0.01–0.08 Hz) fluctuations (LFF) of the
blood oxygenation level-dependent (BOLD) signal in resting
state fMRI data are believed to reflect intrinsic neural activity.
We carried out the fractional amplitude of LFF (fALFF)
analysis on the preprocessed functional data using REST
(http://resting-fmri.sourceforge.net), as previously described
[45]. The fALFF maps of the basal fMRI measurement were
subtracted from the fALFF maps of the 30 min fMRI
measurement for each participant. We took a region-of-
interest approach by using the WFU PickAtlas tool
(http://fmri.wfubmc.edu/software/PickAtlas, accessed 13
February 2015) to extract mean fALFF values of the
striatum, a critical component of the dopaminergic reward
system. Areas of the striatum include the caudate nucleus,
putamen and pallidum. The extracted fALFF values were
then further analysed in a linear regression model.
Calculations Insulin sensitivity during the OGTT was
estimated as 10,000/(G0 × I0 × Gmean × Imean)
1/2, where
G=glucose (in mmol/l) and I = insulin (in pmol/l). AUC was
calculated according to the trapezoid method.
Statistical analysis Data that were not normally distributed
were loge-transformed to approximate a normal distribution
prior to analysis. ANCOVAwas used to identify interactions
between SNPs. Associations were analysed by multiple linear
regression analysis. A p value <0.05 was considered to be
statistically significant; a p value <0.1 was considered to
indicate a trend. The statistical software package JMP (SAS
Institute, Cary, NC, USA) was used for statistical analysis.
Results
Associations with body composition and metabolic traits
in the TUEF cohort Interactions between the FTO SNP
rs8050136 and ANKK1 SNP rs1800497 on body composition
and metabolic traits were investigated by ANCOVA for both
polymorphisms. There were interactions between the two
SNPs for percentage body fat, waist circumference and
waist-to-hip ratio, as well as for the insulin sensitivity index
and fasting insulin in models adjusted for sex and age (all
p<0.05, Table 2). No significant interactions were detected
for lean bodymass, fasting and post-load glycaemia, or insulin
secretion (assessed as insulin30min and AUCC-peptide/
AUCglucose). Repeating the analyses in unadjusted models
revealed comparable results (all p < 0.05), except for
waist-to-hip ratio and the insulin sensitivity index which only
showed trends towards significance (p= 0.1 and p= 0.08,
respectively).
The group was then stratified according to ANKK1
rs1800497 genotype in homozygous carriers of the C allele
vs those carrying at least one copy of the T risk allele (see
Table 2). Associations of FTO rs8050136 were then tested for
both ANKK1 groups separately. The FTO SNP was associated
with body weight and BMI independent of the ANKK1 SNP;
however, the effect sizes were markedly larger in carriers of
the ANKK1 T allele than in CC allele carriers (Table 2). While
the FTO SNP was not associated with body fat content or
waist-to-hip ratio in homozygous carriers of the ANKK1 C
allele (p for additive inheritance model [padd] 0.1, β 0.017
± 0.012, Fig. 1a; padd 0.5, β −0.003 ±0.004, respectively),
associations were found in participants harbouring the T allele
(padd 0.0006, β 0.056±0.016, Fig. 1a; padd 0.03, β 0.017
±0.008, respectively). Furthermore, it was only against the
ANKK1 T allele background that the FTO obesity-risk allele
carriers had a lower insulin sensitivity index and higher fasting
insulin than the FTO non-risk allele carriers (padd 0.0012,
β −0.121 ± 0.037, Fig. 1b; padd 0.0002, β 0.126 ± 0.034,
respectively). This association was not present in the
ANKK1 SNP CC carriers (Table 2, Fig. 1b).
Associations with body composition and metabolic traits
in the MDC cohort In the MDC cohort, interactions between
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the ANKK1 and FTO polymorphisms were detected for waist
circumference and waist-to-hip ratio (Table 3).
Corresponding with the results from the TUEF cohort,
waist circumference was associated with the FTO
polymorphism in participants with the ANKK1 T allele
(padd 0.025, β 0.019±0.008), while no such association was
detected in ANKK1 CC allele carriers (padd 0.2, β −0.005
±0.006). Also the insulin sensitivity index and fasting insulin
levels were only associated with the FTO SNP in ANKK1 T
allele carriers (padd 0.02, β −0.084±0.005; padd 0.04, β 0.078
±0.04, respectively), but not in participants with the ANKK1
CC allele (padd 0.7, β 0.027±0.04; padd 0.9, β −0.001±0.03,
respectively; see Table 3).
Associations with insulin action in the caudate nucleus
Since FTO rs8050136 is known to be linked to brain insulin
sensitivity [24], we investigated how the two polymorphisms
relate to brain insulin action in the striatum, a major
dopaminergic area in the brain in which the ANKK1 SNP is
known to be important [41], following intranasal insulin
administration.
To increase statistical power in this small group, we only
tested dominant inheritance models. As for peripheral insulin
sensitivity, we detected an interaction between the FTO
rs8050136 and ANKK1 rs1800497 SNPs on insulin response
in the caudate nucleus (ANCOVA p for dominant inheritance
model [pdom] 0.0060). While the reaction to insulin did not
differ between FTO genotypes in carriers of the ANKK1 CC
alleles, it differed in the ANKK1 T allele carriers. Therefore,
insulin reduced activity in the caudate nucleus in FTO
non-risk allele carriers, but increased activity in obesity-risk
allele carriers (Fig. 2).
Discussion
In this study, we have demonstrated an interaction between
variations in FTO and the ANKK1/TaqIA polymorphism that
affects body composition, as well as peripheral and central
insulin sensitivity. While the FTO SNP was not associated
with body fat distribution or insulin sensitivity in persons
carrying the ANKK1 non-risk allele, it was associated with
both variables in participants carrying the ANKK1/TaqIA
polymorphism.
These findings, that were replicated in the indepen-
dent MDC cohort, provide further evidence that varia-
tions in FTO influence dopamine signalling in humans
in the same way as predicted from rodents [14].
Specifically, on the basis of the associations between
ANKK1 variations and D2 receptor availability [34,
35], as well as D2 receptor binding potential in humans
[36]. Our results indicate that the FTO polymorphism
investigated here may be less critical when sufficient
D2 receptors are available but it may have adverse ef-
fects when dopaminergic transmission is limited. Given
the high frequency of both polymorphisms in the gen-
eral population, a substantial number of people will car-
ry the risk alleles for both polymorphisms, i.e. in our
study population >20% of the participants carried both
risk alleles. Our results demonstrate that these individ-
uals will be at increased risk for obesity, insulin resis-
tance and type 2 diabetes. Our data also highlight the possi-
bility that in addition to other known environmental perturba-
tions, the identified interaction contributes to the known asso-
ciation of the FTO polymorphism with both obesity and dia-
betes [2, 4].
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Complementing our findings of peripheral markers of
metabolism and obesity, our neuroimaging results show that
the effect of the detected interaction between FTO and
ANKK1 on insulin sensitivity is not limited to peripheral
tissues, but that it also exists in the D2-receptor rich
caudate nucleus. The ANKK1 genotype influenced D2
receptor binding and BOLD responses to the receipt of
palatable and energy-dense food in this region [41, 46].
This is of particular interest since both BOLD response
[47] and dopamine release [48] in the caudate nucleus
following palatable food intake was related to ratings of
meal pleasantness. This demonstrates the importance of
D2 receptor signalling in the caudate nucleus in eating
behaviour and food reward. Interactions between insulin
and dopaminergic networks contribute to both these
brain functions accordingly [20]. Even though brain in-
sulin sensitivity was not specifically tested in animals
lacking Fto in dopaminergic neurons [14], it is tempting
to speculate that altered insulin responses contributed to
the observed phenotype.
There are at least two plausible explanations as to how the
detected interactions in the brain could lead to the observed
peripheral associations with regard to body fat distribution and
systemic metabolism. Dopamine signalling in the brain is a
determinant of peripheral insulin sensitivity [18]. Accordingly,
circulating prolactin, a proxy for dopaminergic tone, has an age-
dependent association with peripheral insulin sensitivity and
glycaemia [49]. Based on our current results, dopaminergic
control over peripheral glucose metabolism could be affected
by FTO genotype.
However, we observed that the known association of the
FTO SNP rs8050136 with brain insulin resistance depends on
functional dopamine signalling, as determined by the ANKK1
polymorphism. The FTO SNP was not associated with insulin
responsiveness in the caudate nucleus in persons carrying the
ANKK1 non-risk allele, while it was associated with regional
brain insulin sensitivity in carriers of the risk allele. In addition
to various other functions, such as memory and reward, insu-
lin delivery to the brain induced weight loss [29, 50]. Brain
insulin sensitivity even predicts loss of metabolically un-
healthy visceral fat during a lifestyle intervention [51].
Furthermore, insulin in the brain was recently shown to mod-
ulate peripheral insulin sensitivity in humans [28, 29].
Impaired brain insulin signalling could therefore contribute
to increased body fat content and increased waist circumfer-
ence, as well as to reduced peripheral insulin sensitivity in
carriers of both risk alleles. In addition, our results in combi-
nation with the finding of an altered midbrain response in
participants carrying both polymorphisms during a reward
learning task [42] indicate that the interaction of FTO and
ANNK1 affects metabolic and behavioural brain networks.
The alterations that we observed in the brain in carriers of
both risk alleles might trigger the alterations in peripheral
metabolism, but we cannot rule out the possibility that the
detected associations in regional brain activity are secondary
to peripheral changes, e.g. altered body fat content. How FTO
variations influence IRX3/5 or RPGRIP1L expression in do-
paminergic neurons and how this relates to their functional
properties has not yet been addressed. Further studies are re-
quired to gain a better understanding of the mechanisms
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Fig. 2 Insulin sensitivity in the caudate nucleus of the striatum (a)
is determined by the obesity-risk polymorphism in FTO and the
D2 receptor polymorphism in ANKK1. Insulin effects on the cau-
date nucleus were assessed by fMRI combined with intranasal
insulin administration in 45 healthy volunteers. (b) Insulin-in-
duced change in caudate activity was determined and participants
were stratified according to their ANKK1 rs1800497 genotype in
CC and XT carriers. FTO rs8050136 genotype is indicated by bar
colour: white bars, FTO CC allele carriers; black bars, FTO XA
obesity-risk allele carriers. There was no association with the FTO
SNP in ANKK1 CC carriers, whereas FTO differed in the striatal
response to insulin under the ANKK1 XT background. Here, FTO
non-risk allele carriers had a reduction in activity while FTO
obesity-risk allele carriers showed an increase. This figure shows
unadjusted means ± SEM. p values are taken from an unadjusted
additive inheritance model. AU, arbitrary units; NS, non-
significant (p > 0.05), *p < 0.05
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underlying our results. Both cohorts that were analysed in this
work only included individuals of European descent, and SNP
rs8050136 may not be a good proxy for the association of the
FTO locus with obesity in cohorts of different ethnicity.
Therefore, our results cannot necessarily be transferred to an-
other population. Thus, replication studies are needed, espe-
cially with participants of different genetic origin. Since we
used a candidate gene approach, additional contributions of
other genetic variants will be missed.
In summary, we report an interaction between the
obesity-risk polymorphism in FTO and the ANKK1/TaqIA
SNP indicating that the ∼20% of the population carrying both
risk alleles have a markedly higher risk for obesity and
diabetes. Our data also suggest that the ANKK1 risk allele
may be a major contributor to the previously reported
influence of FTO on obesity and metabolism.
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